Action AMRX AMNEAL PHARMACEUTICALS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Communiqués Amneal Pharmaceuticals, Inc.

Actions

AMRX

US03168L1052

Temps réel estimé Cboe BZX
Autres places de cotation
 19:48:52 10/06/2024 		Varia. 5j. Varia. 1 janv.
6,84 USD +1,33 % Graphique intraday de Amneal Pharmaceuticals, Inc. +2,27 % +11,37 %
05/06 Transcript : Amneal Pharmaceuticals, Inc. Presents at Jefferies 2024 Global Healthcare Conference, Jun-05-2024 01:30 PM
05/06 Amneal Pharmaceuticals, Inc. élargit son large portefeuille de produits injectables à plus de 40 produits avec l'ajout de six nouvelles thérapies CI

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Amneal Pharmaceuticals : Jefferies Global Healthcare Conference 2024
PU
Amneal Expands Broad Injectables Portfolio to Over 40 Products with the Addition of Six New Therapies
BU
Amneal Begins Supplying Over-the-Counter Naloxone Hydrochloride Nasal Spray to U.S. Retail Pharmacies and the State of California
BU
Amneal to Participate at Upcoming Investor Conference
BU
Amneal Reports First Quarter 2024 Financial Results
AQ
Amneal Pharmaceuticals : First Quarter 2024 Earnings Presentation
PU
Amneal: Q1 Earnings Snapshot
AQ
Amneal Reports First Quarter 2024 Financial Results
BU
California is joining with a New Jersey company to buy a generic opioid overdose reversal drug
AQ
Amneal Announces U.S. FDA Approval of Over-the-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose
BU
Amneal Launches PEMRYDI RTU, the First Ready-to-Use Version of Important Oncology Injectable Medicine
AQ
Amneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable Medicine
BU
Amneal to Report First Quarter 2024 Results on May 3, 2024
BU
Amneal to Ring the Nasdaq Closing Bell on April 2, 2024
BU
Amneal Pharmaceuticals, LLC. Issues a Nationwide Voluntary Recall of Vancomycin Hydrochloride for Oral Solution USP, 250mg/5mL, due to the potential for some bottles to be super potent which may be harmful
AQ
Amneal Pharmaceuticals : LLC. Issues a Nationwide Voluntary Recall of Vancomycin Hydrochloride for Oral Solution USP, 250mg/5mL, due to the potential for some bottles to be super potent which may be harmful.
PU
Amneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension
BU
Amneal Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
AQ
Amneal: Q4 Earnings Snapshot
AQ
Amneal Reports Fourth Quarter and Full Year 2023 Financial Results
BU
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action AMRX
  4. Actualités Amneal Pharmaceuticals, Inc.
  5. Communiqués